---
title: "YILING PHARMACEUTICAL: Wholly-owned subsidiary Anastrozole raw material drug has received the approval notice for listing application"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/263236348.md"
description: "YILING PHARMACEUTICAL's wholly-owned subsidiary, Wanyang Hengshui Pharmaceutical Co., Ltd., has received the notice of approval for the marketing application of anastrozole chemical raw materials from the National Medical Products Administration. Anastrozole is used to treat estrogen-related tumors, particularly in postmenopausal hormone receptor-positive female breast cancer patients. Another wholly-owned subsidiary of YILING PHARMACEUTICAL holds the approval for anastrozole tablet formulation, and integrated production of raw materials and formulations is expected to be achieved this year"
datetime: "2025-10-29T08:19:33.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/263236348.md)
  - [en](https://longbridge.com/en/news/263236348.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/263236348.md)
generator: "portal-rs"
---

# YILING PHARMACEUTICAL: Wholly-owned subsidiary Anastrozole raw material drug has received the approval notice for listing application

YILING PHARMACEUTICAL announced that its wholly-owned subsidiary, Wanyang Hengshui Pharmaceutical Co., Ltd., has received the "Approval Notice for the Listing Application of Chemical Raw Materials" issued by the National Medical Products Administration, and the listing application for Anastrozole chemical raw materials has been approved. Anastrozole is a drug widely used in the treatment of estrogen-related tumors, especially in postmenopausal hormone receptor-positive female breast cancer patients. YILING PHARMACEUTICAL's wholly-owned subsidiary, Beijing Yiling Biotechnology Co., Ltd., holds the approval for Anastrozole tablet formulations, which are centralized procurement products, and it is expected that integrated production of raw materials and formulations can be achieved this year

### Related Stocks

- [002603.CN](https://longbridge.com/en/quote/002603.CN.md)

## Related News & Research

- [Vishnusurya Projects and Infra's (NSE:VISHNUINFR) Weak Earnings May Only Reveal A Part Of The Whole Picture](https://longbridge.com/en/news/305559929.md)
- [Pondy Oxides And Chemicals Limited Just Missed Earnings And Its Revenue Numbers Were Weaker Than Expected](https://longbridge.com/en/news/305560101.md)
- [RioCan Real Estate Investment Trust (TSX:REI.UN) Expands Its Buyback Program, Is It Still Undervalued?](https://longbridge.com/en/news/305557624.md)
- [Kava Lend loses roughly $3.8 million to hack, sending KAVA token down nearly 40%](https://longbridge.com/en/news/305556359.md)
- [Servier Presents Updated Four-Year Results from Phase 2 FIREFLY-1 Study of OJEMDA® (tovorafenib) in Pediatric Low-Grade Glioma (pLGG) at SNO 2026](https://longbridge.com/en/news/305554906.md)

---
> **Disclaimer: This article is for reference only and does not constitute any investment advice.**